|
|
The safety, tolerability and pharmacokinetics of a single intravenous infusion of 10, 40 and 80 ?g/kg XG-102 administered to healthy male volunteers in a randomized, double blind, placebo controlled, dose escalating Phase I study, Sponsor protocol identif
| Third-party funded project |
| Project title |
The safety, tolerability and pharmacokinetics of a single intravenous
infusion of 10, 40 and 80 ?g/kg XG-102 administered to healthy male
volunteers in a randomized, double blind, placebo controlled, dose
escalating Phase I study,
Sponsor protocol identifying number: SDD-1002-024
CRO protocol identifying number: BCRU560-1 |
| Principal Investigator(s) |
Prünte, Christian
|
| Organisation / Research unit |
Bereich Spezialfächer (Klinik) / Ophthalmologie USB |
| Project start |
01.07.2011 |
| Probable end |
31.10.2011 |
| Status |
Completed |
| Abstract |
Fördergeber: Convance Clinical Research, Unit AG, Lettenweg 118, CH-4123 Allschwil, Diese Studie war eine Auftragsarbeit, daher haben wir den Betrag von 19666 CHF erhalten.
(The safety, tolerability and pharmacokinetics of a single intravenous
infusion of 10, 40 and 80 ?g/kg XG-102 administered to healthy male
Keine Fördergelder von Basel!
volunteers in a randomized, double blind, placebo controlled, dose
escalating Phase I study,
Sponsor protocol identifying number: SDD-1002-024
CRO protocol identifying number: BCRU560-1) |
| Financed by |
Other sources
|
| |
|
|
MCSS v5.8 PRO. 0.429 sec, queries - 0.000 sec
©Universität Basel | Impressum
|  |
|
05/05/2024
Research Database / FORSCHUNGSDATENBANK
|
